[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Schiedner et al., 2002 - Google Patents

Variables affecting in vivo performance of high-capacity adenovirus vectors

Schiedner et al., 2002

View PDF @Full View
Document ID
1546508265531711176
Author
Schiedner G
Hertel S
Johnston M
Biermann V
Dries V
Kochanek S
Publication year
Publication venue
Journal of virology

External Links

Snippet

In high-capacity adenovirus (HC-Ad) vectors the size and/or composition of the vector genome influences vector stability during production and the expression profile following gene transfer. Typically, an HC-Ad vector will contain both a gene or an expression cassette …
Continue reading at journals.asm.org (PDF) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses
    • C12N2710/00011—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses dsDNA Viruses
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses
    • C12N2710/00011—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses dsDNA Viruses
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Similar Documents

Publication Publication Date Title
Schiedner et al. Variables affecting in vivo performance of high-capacity adenovirus vectors
Reddy et al. Sustained human factor VIII expression in hemophilia A mice following systemic delivery of a gutless adenoviral vector
Parks et al. Effects of stuffer DNA on transgene expression from helper-dependent adenovirus vectors
Parks et al. Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration
Andrews et al. Generation and characterization of E1/E2a/E3/E4-deficient adenoviral vectors encoding human factor VIII
Amalfitano et al. Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted
Ng et al. Development of a FLP/frt system for generating helper-dependent adenoviral vectors
Amalfitano et al. Separating fact from fiction: assessing the potential of modified adenovirus vectors for use in human gene therapy
Zhang et al. Role for the adenovirus IVa2 protein in packaging of viral DNA
Harui et al. Frequency and stability of chromosomal integration of adenovirus vectors
Gorziglia et al. Generation of an adenovirus vector lacking E1, e2a, E3, and all of E4 except open reading frame 3
Lusky et al. In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted
Palmer et al. Helper-dependent adenoviral vectors for gene therapy
Morsy et al. Expanded-capacity adenoviral vectors—the helper-dependent vectors
Sandig et al. Optimization of the helper-dependent adenovirus system for production and potency in vivo
Jooss et al. Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers
Muruve et al. Helper-dependent adenovirus vectors elicit intact innate but attenuated adaptive host immune responses in vivo
Ehrhardt et al. Episomal persistence of recombinant adenoviral vector genomes during the cell cycle in vivo
Kremer et al. Adenovirus and adeno-associated virus mediated gene transfer
Parks et al. An enhanced system for construction of adenoviral vectors by the two-plasmid rescue method
Schiedner et al. Selective depletion or blockade of Kupffer cells leads to enhanced and prolonged hepatic transgene expression using high-capacity adenoviral vectors
Hofmann et al. Ovine adenovirus vectors overcome preexisting humoral immunity against human adenoviruses in vivo
Mitani et al. Adenovirus as an integrating vector
Hartigan-O’Connor et al. Improved production of gutted adenovirus in cells expressing adenovirus preterminal protein and DNA polymerase
Parks Improvements in adenoviral vector technology: overcoming barriers for gene therapy.